ECT & CRP, quo vadis? - A retrospective study of low-grade inflammation in patients with depression undergoing electroconvulsive therapy

Introduction: Electroconvulsive therapy (ECT) is the most effective treatment for severe depression. Depression has been associated with low-grade inflammation (LGI), as indicated by elevated C-reactive protein (CRP) levels compared to healthy individuals. While the effect of ECT on inflammation mar...

Full description

Saved in:
Bibliographic Details
Main Authors: Moritz Spangemacher, Sebastian Karl, Suna Su Aksay, Eva Kathrin Lamadé, Jana Plemper, Alexander Sartorius, Bruno Pedraz-Petrozzi
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Biomarkers in Neuropsychiatry
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666144624000339
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850251185098850304
author Moritz Spangemacher
Sebastian Karl
Suna Su Aksay
Eva Kathrin Lamadé
Jana Plemper
Alexander Sartorius
Bruno Pedraz-Petrozzi
author_facet Moritz Spangemacher
Sebastian Karl
Suna Su Aksay
Eva Kathrin Lamadé
Jana Plemper
Alexander Sartorius
Bruno Pedraz-Petrozzi
author_sort Moritz Spangemacher
collection DOAJ
description Introduction: Electroconvulsive therapy (ECT) is the most effective treatment for severe depression. Depression has been associated with low-grade inflammation (LGI), as indicated by elevated C-reactive protein (CRP) levels compared to healthy individuals. While the effect of ECT on inflammation markers remains unclear, some evidence suggests that higher baseline CRP levels may predict remission in ECT. Additionally, LGI could influence the seizure threshold and thus the required stimulation dose. Materials and methods: This retrospective study examined the potential link between LGI and treatment outcomes as well as stimulation doses across multiple ECT sessions, controlling for age and interparticipant variability. The hypothesis of this study was that LGI was associated with ECT remission as well as with ECT dosing in people with depression. Two groups were defined, depending on CRP levels, those with LGI (CRP 3–10 mg/L) and those without (CRP < 3 mg/L). Generalized linear models were used to analyze maximum ECT doses, while linear mixed models were applied to assess changes in ECT doses over time. Results: After 10 ECT sessions, we found no significant difference in remission rates between patients with (n = 52) and without LGI (n = 143). However, patients with baseline LGI had higher maximum ECT doses. A linear mixed model revealed that the number of sessions and baseline LGI significantly influenced ECT doses, with patients with baseline LGI needing higher doses, particularly at the seventh session. Age also was associated with both maximum doses and dose adjustments throughout the ECT series, but the influence of LGI on ECT dose was independent of age, since no age differences were observed between groups. Conclusions: Baseline inflammation was not associated with remission rates, but it had a significant association with ECT dosing. Therefore, while CRP may not be a reliable biomarker for predicting ECT response in depression, baseline inflammation could indicate the need for a higher stimulation dose.
format Article
id doaj-art-54f7cbfc38b24fd0ad40a9bd394eef61
institution OA Journals
issn 2666-1446
language English
publishDate 2025-06-01
publisher Elsevier
record_format Article
series Biomarkers in Neuropsychiatry
spelling doaj-art-54f7cbfc38b24fd0ad40a9bd394eef612025-08-20T01:57:58ZengElsevierBiomarkers in Neuropsychiatry2666-14462025-06-011210011510.1016/j.bionps.2024.100115ECT &amp; CRP, quo vadis? - A retrospective study of low-grade inflammation in patients with depression undergoing electroconvulsive therapyMoritz Spangemacher0Sebastian Karl1Suna Su Aksay2Eva Kathrin Lamadé3Jana Plemper4Alexander Sartorius5Bruno Pedraz-Petrozzi6Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, J5, 68159 Mannheim, Medical Faculty Mannheim - University of Heidelberg, Mannheim, Germany; Department of Molecular Neuroimaging, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; German Center for Mental Health (DZPG), partner site Mannheim, Germany; Research Group Brain Stimulation, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Corresponding author at: Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, J5, 68159 Mannheim, Medical Faculty Mannheim - University of Heidelberg, Mannheim, GermanyDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, J5, 68159 Mannheim, Medical Faculty Mannheim - University of Heidelberg, Mannheim, Germany; German Center for Mental Health (DZPG), partner site Mannheim, Germany; Research Group Brain Stimulation, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, GermanyDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, J5, 68159 Mannheim, Medical Faculty Mannheim - University of Heidelberg, Mannheim, Germany; German Center for Mental Health (DZPG), partner site Mannheim, Germany; Research Group Brain Stimulation, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, GermanyDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, J5, 68159 Mannheim, Medical Faculty Mannheim - University of Heidelberg, Mannheim, Germany; German Center for Mental Health (DZPG), partner site Mannheim, Germany; Research Group of Stress-related Disorders, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Research Group Brain Stimulation, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, GermanyDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, J5, 68159 Mannheim, Medical Faculty Mannheim - University of Heidelberg, Mannheim, Germany; Research Group Brain Stimulation, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, GermanyDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, J5, 68159 Mannheim, Medical Faculty Mannheim - University of Heidelberg, Mannheim, Germany; German Center for Mental Health (DZPG), partner site Mannheim, Germany; Research Group Brain Stimulation, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, GermanyDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, J5, 68159 Mannheim, Medical Faculty Mannheim - University of Heidelberg, Mannheim, Germany; German Center for Mental Health (DZPG), partner site Mannheim, Germany; Research Group of Stress-related Disorders, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Research Group Brain Stimulation, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, GermanyIntroduction: Electroconvulsive therapy (ECT) is the most effective treatment for severe depression. Depression has been associated with low-grade inflammation (LGI), as indicated by elevated C-reactive protein (CRP) levels compared to healthy individuals. While the effect of ECT on inflammation markers remains unclear, some evidence suggests that higher baseline CRP levels may predict remission in ECT. Additionally, LGI could influence the seizure threshold and thus the required stimulation dose. Materials and methods: This retrospective study examined the potential link between LGI and treatment outcomes as well as stimulation doses across multiple ECT sessions, controlling for age and interparticipant variability. The hypothesis of this study was that LGI was associated with ECT remission as well as with ECT dosing in people with depression. Two groups were defined, depending on CRP levels, those with LGI (CRP 3–10 mg/L) and those without (CRP < 3 mg/L). Generalized linear models were used to analyze maximum ECT doses, while linear mixed models were applied to assess changes in ECT doses over time. Results: After 10 ECT sessions, we found no significant difference in remission rates between patients with (n = 52) and without LGI (n = 143). However, patients with baseline LGI had higher maximum ECT doses. A linear mixed model revealed that the number of sessions and baseline LGI significantly influenced ECT doses, with patients with baseline LGI needing higher doses, particularly at the seventh session. Age also was associated with both maximum doses and dose adjustments throughout the ECT series, but the influence of LGI on ECT dose was independent of age, since no age differences were observed between groups. Conclusions: Baseline inflammation was not associated with remission rates, but it had a significant association with ECT dosing. Therefore, while CRP may not be a reliable biomarker for predicting ECT response in depression, baseline inflammation could indicate the need for a higher stimulation dose.http://www.sciencedirect.com/science/article/pii/S2666144624000339Electroconvulsive therapyTreatment responseDepressionC-reactive proteinLow-grade inflammation
spellingShingle Moritz Spangemacher
Sebastian Karl
Suna Su Aksay
Eva Kathrin Lamadé
Jana Plemper
Alexander Sartorius
Bruno Pedraz-Petrozzi
ECT &amp; CRP, quo vadis? - A retrospective study of low-grade inflammation in patients with depression undergoing electroconvulsive therapy
Biomarkers in Neuropsychiatry
Electroconvulsive therapy
Treatment response
Depression
C-reactive protein
Low-grade inflammation
title ECT &amp; CRP, quo vadis? - A retrospective study of low-grade inflammation in patients with depression undergoing electroconvulsive therapy
title_full ECT &amp; CRP, quo vadis? - A retrospective study of low-grade inflammation in patients with depression undergoing electroconvulsive therapy
title_fullStr ECT &amp; CRP, quo vadis? - A retrospective study of low-grade inflammation in patients with depression undergoing electroconvulsive therapy
title_full_unstemmed ECT &amp; CRP, quo vadis? - A retrospective study of low-grade inflammation in patients with depression undergoing electroconvulsive therapy
title_short ECT &amp; CRP, quo vadis? - A retrospective study of low-grade inflammation in patients with depression undergoing electroconvulsive therapy
title_sort ect amp crp quo vadis a retrospective study of low grade inflammation in patients with depression undergoing electroconvulsive therapy
topic Electroconvulsive therapy
Treatment response
Depression
C-reactive protein
Low-grade inflammation
url http://www.sciencedirect.com/science/article/pii/S2666144624000339
work_keys_str_mv AT moritzspangemacher ectampcrpquovadisaretrospectivestudyoflowgradeinflammationinpatientswithdepressionundergoingelectroconvulsivetherapy
AT sebastiankarl ectampcrpquovadisaretrospectivestudyoflowgradeinflammationinpatientswithdepressionundergoingelectroconvulsivetherapy
AT sunasuaksay ectampcrpquovadisaretrospectivestudyoflowgradeinflammationinpatientswithdepressionundergoingelectroconvulsivetherapy
AT evakathrinlamade ectampcrpquovadisaretrospectivestudyoflowgradeinflammationinpatientswithdepressionundergoingelectroconvulsivetherapy
AT janaplemper ectampcrpquovadisaretrospectivestudyoflowgradeinflammationinpatientswithdepressionundergoingelectroconvulsivetherapy
AT alexandersartorius ectampcrpquovadisaretrospectivestudyoflowgradeinflammationinpatientswithdepressionundergoingelectroconvulsivetherapy
AT brunopedrazpetrozzi ectampcrpquovadisaretrospectivestudyoflowgradeinflammationinpatientswithdepressionundergoingelectroconvulsivetherapy